List view / Grid view
Researchers have developed a two-step approach using whole exome sequencing to focus on genes and pathways that predict whether cancer patients will respond to immunotherapy.
In a new study, researchers have shared the identification of a new potential target for CAR T cells that inhibits growth in lung and ovarian tumours.
Scientists have developed CRISPR with a new process that evaluates the impacts of gene edits that alter rather than deleting DNA code.
A new study from the University of Michigan Rogel Cancer Center, US has revealed that a cytokine and a fatty acid can work together to trigger ferroptosis. Here, Dr Weiping Zou, the lead researcher from the study, outlines how this process could be used to target cancer cells and enhance immunotherapies.
A new study has highlighted an enzyme called ART1 as a promising target for immunity-boosting cancer treatments.
The new study looked at the network of gene-gene interactions associated with cancer onset and progression to identify therapeutic targets.
New research has revealed that club cells secret anti-immunosuppressive factors in tumours, potentially revolutionising cancer therapies.
An NIH study used whole genome sequencing to describe three molecular subtypes of lung cancer in non-smokers, possibly improving treatments.
Researchers created their new method to analyse chromosomes in 3D, revealing how misconfigurations play a role in cancer.
A spatial atlas of early-stage lung cancer has been compiled at single-cell resolution, revealing new therapeutic targets.
Having synthesised the curcusone D compound, researchers demonstrated its promise as the first BRAT1 inhibitor, making it a potential cancer therapy.
Jim Shanahan from SynDevRx explains why metabo-oncology treatment modalities could be the answer to a rise in metabolic disorders and cancers.
New research shows tissue damage to cells carrying KRAS mutations induces epigenetic changes that promote pancreatic cancer.
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
When it comes to developing antibody drugs, Dr Jerome Boyd-Kirkup and his team are not sticking to the classical playbook. Here, he explains how they use systems biology and immuno-engineering to remove the element of luck from biologic drug discovery and development.
